作者
Irene M Ghobrial, Rafael Fonseca, Philip R Greipp, Emily Blood, Montserrat Rue, David H Vesole, Morie A Gertz
发表日期
2004/12/1
期刊
Cancer: Interdisciplinary International Journal of the American Cancer Society
卷号
101
期号
11
页码范围
2593-2598
出版商
Wiley Subscription Services, Inc., A Wiley Company
简介
BACKGROUND
The goal of the current study was to characterize the initial upsurge in immunoglobulin M (IgM) levels after treatment with rituximab in patients with Waldenstrom macroglobulinemia (WM).
METHODS
As part of a Phase II Eastern Cooperative Oncology Group study, 72 patients were treated with rituximab (375 mg/m2 weekly for 4 weeks) between April 2000 and January 2002. IgM levels in these patients were measured at five separate time points so that any temporal changes that occurred could be characterized.
RESULTS
Of the 54 patients for whom the relevant IgM measurements were available, 29 (54%) experienced an increase in IgM levels between baseline and the first scheduled postbaseline time point. At 2 months, 13 of 22 evaluable patients (59%) continued to have elevated IgM levels, and at 4 months, elevated IgM levels persisted in 4 of 15 evaluable patients (27%). Overall, a …
引用总数
学术搜索中的文章
IM Ghobrial, R Fonseca, PR Greipp, E Blood, M Rue… - Cancer: Interdisciplinary International Journal of the …, 2004